Tuesday, October 8, 2013

Biosensors International -NRA-SGX Seminar - Healthcare Part (NRA)

Biosensors International
Current Price S$0.94
52-low S$0.82
52-high S$1.42

Background
Biosensors International Group, Ltd., an investment holding company, engages in the research and development, manufacture, assembly, marketing, distribution, and sale of medical devices for interventional cardiology and critical care procedures worldwide. It operates through three segments: Interventional Cardiology, Critical Care, and Licensing Revenue.
The Interventional Cardiology segment supplies its proprietary drug-eluting stent products, coronary bare-metal stents, accompanying stent delivery balloon catheter systems, angioplasty balloons, and catheters under the BioMatrix Flex, BioMatrix NeoFlex, Axxess, BioFreedom, Gazelle, and Powerline brand names. The Critical Care segment supplies catheter systems and related accessories that are used in surgeries, and intensive care treatment and monitoring procedures. It offers its products under the ACCUTRANS, BIOTRANS, and BIOTRAY brand names. The Licensing Revenue segment engages in the licensing of its proprietary drug-eluting stent technology and intellectual property. The company was founded in 1990 and is headquartered in Singapore.

Recent Financial Overview
Biosensors’s 1Q14 revenue down 11% yoy to US$76.7m mainly due to channel inventory adjustment in China and lower royalty and licensing revenues (-33% yoy). Products’ gross profit margins were down from 81% to 75% in the quarter due to lower gross margin for the company’s IVP product line as a result of its distribution activities in Japan for the Nobori stents, coupled with higher operating expenses, net profit declined by 57% yoy to US$12m (excluding exceptional items).

Outlook
For the fiscal year ending 31 March 2014, management maintains its previous guidance and continues to expect total revenue to grow by around 15% over FY13. This guidance is driven primarily by continued product revenue growth in the EMEA and APAC regions, as well as the expectation that China sales will recover following the inventory adjustment in Q114. New revenues are also expected from the commercialisation of various new products and the newly acquired business of Spectrum Dynamics. The company expects its aggregate royalty income to improve over its Q114 results.


Source/Extract/Excerpts/来源/转贴/摘录: NRA-Research,
Publish date: 12/09/13

No comments:

Post a Comment

Warren E. Buffett(沃伦•巴菲特)
Be fearful when others are greedy, and be greedy when others are fearful
别人贪婪时我恐惧, 别人恐惧时我贪婪
投资只需学好两门课: 一,是如何给企业估值,二,是如何看待股市波动
吉姆·罗杰斯(Jim Rogers)
“错过时机”胜于“搞错对象”:不会全军覆没!”
做自己熟悉的事,等到发现大好机会才投钱下去

乔治·索罗斯(George Soros)

“犯错误并没有什么好羞耻的,只有知错不改才是耻辱。”

如果操作过量,即使对市场判断正确,仍会一败涂地。

李驰(中国巴菲特)
高估期间, 卖对, 不卖也对, 买是错的。
低估期间, 买对, 不买也是对, 卖是错的。

Tan Teng Boo


There’s no such thing as defensive stocks.Every stock can be defensive depending on what price you pay for it and what value you get,
冷眼(冯时能)投资概念
“买股票就是买公司的股份,买股份就是与陌生人合股做生意”。
合股做生意,则公司股份的业绩高于一切,而股票的价值决定于盈利。
价值是本,价格是末,故公司比股市重要百倍。
曹仁超-香港股神/港股明灯
1.有智慧,不如趁势
2.止损不止盈
成功者所以成功,是因为不怕失败!失败者所以失败,是失败后不再尝试!
曾淵滄-散户明灯
每逢灾难就是机会,而是在灾难发生时贱价买股票,然后放在一边,耐性地等灾难结束
  • Selected Indexes 52 week range

  • Margin of Safety

    Investment Clock

    World's First Interactive Investment Clock